Eli Lilly now offers higher doses of its weight-loss drug Zepbound in vial form at a discount to the injector pen versions.

Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at ...

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

Some health experts have call for further investigation, as figures show 82 deaths with suspected links to slimming drugs ...

New research finds older women achieve the best results with weight loss injections – thanks to consistent tracking and ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Pfizer appoints Patrizia Cavazzoni as chief medical officer, the U.S. delays the definition of 'healthy' on labels, issues ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...

Hims & Hers Health shares plunged in extended trading Monday after the online healthcare provider reported falling margins as costs rose.

On Friday, the US Food and Drug Administration announced drugs Wegovy and Ozempic by Novo Nordisk are no longer in shortage.

While the outcomes can be positive, Consumer Reports warns there are important considerations, especially for older adults, ...

Delivery apps are allowing Chinese citizens to get their hands on the popular weight-loss and diabetes drugs at the touch of ...